Recently, Jingze Bio's core pipeline project JZB32 (Recombinant Human Truncated Plasminogen Injection) was officially included in the National Science and Technology Major Project for Innovative Drug R&D, under the initiative "Innovative Drug R&D for Major Fundus Diseases Based on Cell Growth Factors."
On July 5, 2026, the project kick-off meeting was grandly held at Wenzhou Medical University, bringing together top experts in ophthalmology and pharmaceutical sciences from across China to conduct in-depth discussions on collaborative R&D of original biologics for fundus diseases.
This marks a national-level honor for Jingze Bio in the field of innovative drug R&D, and signifies that the company's technological strength and strategic positioning in fundus disease innovative drug development have received high recognition at the national level.
JZB32 is a recombinant human truncated plasminogen (Ocriplasmin) injection independently developed by Jingze Bio, intended for the treatment of symptomatic vitreomacular adhesion (sVMA). Currently, there is no specific therapeutic drug for sVMA in China. Even with early diagnosis, patients can only undergo conservative observation until vision is severely impaired, at which point they must resort to vitrectomy—a highly invasive ophthalmic surgical procedure—to physically release the adhesion and barely preserve vision. JZB32 is the first and only drug product under development for sVMA in China.
"Innovative Drug R&D for Major Fundus Diseases Based on Cell Growth Factors" is one of the key priority directions of the National Science and Technology Major Project for Innovative Drug R&D in 2026. The project is led by Wenzhou Medical University and brings together collaborative efforts from multiple universities, hospitals, and pharmaceutical companies, including Tsinghua University, Zhejiang University, Zhejiang University of Technology, Shengdi Pharmaceutical, Rongchang Biopharma, Jingze Bio, Anlong Biotech, and Beijing Tongren Hospital.
Experts at the meeting unanimously agreed that the project stands out for its originality, addresses urgent clinical needs, and holds immense potential for industrial impact, with the promise to fill the domestic gap in biologics for fundus regeneration and repair. As one of the core participating units in the project, Jingze Bio will leverage its technological accumulation and R&D advantages in ophthalmic biologics to fully advance the clinical research and industrialization process of JZB32.
Efung Capital participated in multiple rounds of investment in Jingze Bio from 2019 to 2023. Looking ahead, Efung will continue to deepen its presence in the frontier tracks of biomedicine, fully leveraging its capital and industrial ecosystem advantages in cell therapy, regenerative medicine, and ophthalmic innovative drugs. We will accompany and empower our portfolio companies in accelerating clinical translation and industrialization, contributing Efung's strength to the cause of human health.
END